Identification of Potential Diagnostic Biomarkers for Parkinson's Disease

Overview

Journal FEBS Open Bio

Specialty Biology

Date 2019 Jun 15

PMID 31199560

Citations 25

Authors

Fenghua Jiang

Qianqian Wu

Shuqian Sun

Guanghui Bi

Ling Guo

Affiliations

Soon will be listed here.

Abstract

The identification of biomarkers for early diagnosis of Parkinson's disease (PD) prior to the onset of symptoms may improve the effectiveness of therapy. To identify potential biomarkers, we downloaded microarray datasets of PD from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) between PD and normal control (NC) groups were obtained, and the feature selection procedure and classification model were used to identify optimal diagnostic gene biomarkers for PD. A total of 1229 genes (640 up-regulated and 589 down-regulated) were obtained for PD, and nine DEGs (PTGDS, GPX3, SLC25A20, CACNA1D, LRRN3, POLR1D, ARHGAP26, TNFSF14 and VPS11) were selected as optimal PD biomarkers with great diagnostic value. These nine DEGs were significantly enriched in regulation of circadian sleep/wake cycle, sleep and gonadotropin-releasing hormone signaling pathway. Finally, we examined the expression of GPX3, SLC25A20, LRRN3 and POLR1D in blood samples of patients with PD by qRT-PCR. GPX3, LRRN3 and POLR1D exhibited the same expression pattern as in our analysis. In conclusion, this study identified nine DEGs that may serve as potential biomarkers of PD.

Citing Articles

The Role of ETNPPL in Dopaminergic Neuron Stability: Insights from Neuromelanin-Associated Protein Expression in Parkinson's Disease.

Schillaci F, Lanza G, Salluzzo M, LEpiscopo F, Ferri R, Salemi M Int J Mol Sci. 2024; 25(23).

PMID: 39684817 PMC: 11642302. DOI: 10.3390/ijms252313107.

Novel susceptibility genes and biomarkers for obstructive sleep apnea: insights from genetic and inflammatory proteins.

Zhao Y, Jiang Y, Wang Y, Zhang H, Zhu J, Jiang X Sleep. 2024; 48(2).

PMID: 39087877 PMC: 11808066. DOI: 10.1093/sleep/zsae169.

Analysis of , , , and Gene Expression in the Peripheral Blood of Patients in the Early Stages of Parkinson's Disease.

Shulskaya M, Semenova E, Rudenok M, Partevian S, Lukashevich M, Karabanov A Biomedicines. 2024; 12(7).

PMID: 39061965 PMC: 11273708. DOI: 10.3390/biomedicines12071391.

Insights into the Role of Glutathione Peroxidase 3 in Non-Neoplastic Diseases.

Zhang N, Liao H, Lin Z, Tang Q Biomolecules. 2024; 14(6).

PMID: 38927092 PMC: 11202029. DOI: 10.3390/biom14060689.

Non-HLA angiotensin-type-1 receptor autoantibodies mediate the long-term loss of grafted neurons in Parkinson's disease models.

Rodriguez-Perez A, Garrido-Gil P, Garcia-Garrote M, Munoz A, Parga J, Labandeira-Garcia J Stem Cell Res Ther. 2024; 15(1):138.

PMID: 38735991 PMC: 11089721. DOI: 10.1186/s13287-024-03751-y.

References

Dahm L, Ott C, Steiner J, Stepniak B, Teegen B, Saschenbrecker S . Seroprevalence of autoantibodies against brain antigens in health and disease. Ann Neurol. 2014; 76(1):82-94. DOI: 10.1002/ana.24189. View

Raposo M, Bettencourt C, Maciel P, Gao F, Ramos A, Kazachkova N . Novel candidate blood-based transcriptional biomarkers of Machado-Joseph disease. Mov Disord. 2015; 30(7):968-75. DOI: 10.1002/mds.26238. View

Gaki G, Papavassiliou A . Oxidative stress-induced signaling pathways implicated in the pathogenesis of Parkinson's disease. Neuromolecular Med. 2014; 16(2):217-30. DOI: 10.1007/s12017-014-8294-x. View

Hassanzadeh K, Rahimmi A . Oxidative stress and neuroinflammation in the story of Parkinson's disease: Could targeting these pathways write a good ending?. J Cell Physiol. 2018; 234(1):23-32. DOI: 10.1002/jcp.26865. View

Chi J, Xie Q, Jia J, Liu X, Sun J, Deng Y . Integrated Analysis and Identification of Novel Biomarkers in Parkinson's Disease. Front Aging Neurosci. 2018; 10:178. PMC: 6016006. DOI: 10.3389/fnagi.2018.00178. View

Catterall W, Perez-Reyes E, Snutch T, Striessnig J . International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol Rev. 2005; 57(4):411-25. DOI: 10.1124/pr.57.4.5. View

Pedroso J, Franca Jr M, Braga-Neto P, DAbreu A, Saraiva-Pereira M, Saute J . Nonmotor and extracerebellar features in Machado-Joseph disease: a review. Mov Disord. 2013; 28(9):1200-8. DOI: 10.1002/mds.25513. View

Berger S, Bartsch D . The role of L-type voltage-gated calcium channels Cav1.2 and Cav1.3 in normal and pathological brain function. Cell Tissue Res. 2014; 357(2):463-76. DOI: 10.1007/s00441-014-1936-3. View

Wirdefeldt K, Adami H, Cole P, Trichopoulos D, Mandel J . Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol. 2011; 26 Suppl 1:S1-58. DOI: 10.1007/s10654-011-9581-6. View

10.

Duke D, Moran L, Pearce R, Graeber M . The medial and lateral substantia nigra in Parkinson's disease: mRNA profiles associated with higher brain tissue vulnerability. Neurogenetics. 2007; 8(2):83-94. DOI: 10.1007/s10048-006-0077-6. View

11.

Harrington M, Fonteh A, Biringer R, Huhmer A, Cowan R . Prostaglandin D synthase isoforms from cerebrospinal fluid vary with brain pathology. Dis Markers. 2006; 22(1-2):73-81. PMC: 3851407. DOI: 10.1155/2006/241817. View

12.

Dias V, Junn E, Mouradian M . The role of oxidative stress in Parkinson's disease. J Parkinsons Dis. 2013; 3(4):461-91. PMC: 4135313. DOI: 10.3233/JPD-130230. View

13.

Soreq L, Salomonis N, Bronstein M, Greenberg D, Israel Z, Bergman H . Small RNA sequencing-microarray analyses in Parkinson leukocytes reveal deep brain stimulation-induced splicing changes that classify brain region transcriptomes. Front Mol Neurosci. 2013; 6:10. PMC: 3652308. DOI: 10.3389/fnmol.2013.00010. View

14.

Scherzer C, Eklund A, Morse L, Liao Z, Locascio J, Fefer D . Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A. 2007; 104(3):955-60. PMC: 1766335. DOI: 10.1073/pnas.0610204104. View

15.

Shamir R, Klein C, Amar D, Vollstedt E, Bonin M, Usenovic M . Analysis of blood-based gene expression in idiopathic Parkinson disease. Neurology. 2017; 89(16):1676-1683. PMC: 5644465. DOI: 10.1212/WNL.0000000000004516. View

16.

Niranjan R . The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson's disease: focus on astrocytes. Mol Neurobiol. 2013; 49(1):28-38. DOI: 10.1007/s12035-013-8483-x. View

17.

Aarsland D, Creese B, Politis M, Chaudhuri K, Ffytche D, Weintraub D . Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017; 13(4):217-231. PMC: 5643027. DOI: 10.1038/nrneurol.2017.27. View

18.

Chen L, Yang J, Lu J, Cao S, Zhao Q, Yu Z . Identification of aberrant circulating miRNAs in Parkinson's disease plasma samples. Brain Behav. 2018; 8(4):e00941. PMC: 5893342. DOI: 10.1002/brb3.941. View

19.

Margis R, Margis R, R M Rieder C . Identification of blood microRNAs associated to Parkinsonĭs disease. J Biotechnol. 2011; 152(3):96-101. DOI: 10.1016/j.jbiotec.2011.01.023. View

20.

Atz M, Walsh D, Cartagena P, Li J, Evans S, Choudary P . Methodological considerations for gene expression profiling of human brain. J Neurosci Methods. 2007; 163(2):295-309. PMC: 3835340. DOI: 10.1016/j.jneumeth.2007.03.022. View